Klotho Neurosciences Signs LOI to Acquire Turn Biotechnologies Assets

Klotho Neurosciences (Nasdaq: KLTO) has signed a Letter of Intent (LOI) to acquire select assets from Turn Biotechnologies, including its ERA platform and eTurna RNA delivery system. The proposed cash and stock deal is subject to due diligence, a definitive agreement, and customary closing conditions, aiming to expand Klotho’s longevity therapeutics portfolio.

Innovative Technologies Target Regenerative Therapies

Turn’s proprietary platforms focus on epigenetic reprogramming of age and RNA-based cell rejuvenation. These technologies have potential applications across dermatology, ophthalmology, immunology, osteoarthritis, muscle health, and neurodegenerative diseases such as ALS, positioning Klotho to lead in the rapidly growing field of regenerative medicine and age-related therapeutic development.

$300 Million Global Pharma Partnership Anchors Deal

The acquisition is anchored by a $300 million global pharma partnership, providing strategic financial support and accelerating Klotho’s development pipeline. Analysts expect the deal to enhance Klotho’s competitiveness in longevity research, open new global collaborations, and strengthen its position in the emerging market for next-generation regenerative therapeutics.